Hao-Wei Wang, M.D., Ph.D.
Dr. Wang's primary research interests include the pathogenesis of lymphomas and biomarkers in hematologic malignancies. His research is focused on the genetic alterations and resultant cellular changes that lead to lymphomagenesis. He is also interested in the pathogenesis of virus (e.g., Kaposi sarcoma herpesvirus) associated lymphoproliferative disorders. Additionally, he seeks to advance the diagnosis and minimal residual diseases detection of hematologic malignancies by incorporating new biomarkers in multiparametric flow cytometry.
Dr. Wang is a hematopathologist in the Laboratory of Pathology. He has been actively working on the genetic and epigenetic landscapes of T-cell lymphomas. He also has expertise in virus-associated lymphoproliferative disorders, such as Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease and primary effusion lymphoma. He is developing new tools to improve the diagnosis and stratification of these diseases. He is also developing new strategies in multiparametric flow cytometry for detection of minimal residual diseases, characterization of therapeutic targets and monitoring of adoptively transferred immune cells in the era of cancer immunotherapy.
Selected Recent Publications
Molecular assessment of clonality in lymphoid neoplasms.Seminars in Hematology. in press, 2018.
- British Journal of Haematology. Epub ahead of print, 2018. [ Journal Article ]
STAT3 and STAT6 signaling pathways synergize to promote cathepsin secretion from macrophages via IRE1α activation.Cell Reports. 16(11): 2914-2927, 2016. [ Journal Article ]
- Seminars in Diagnostic Pathology. 33(5): 294-306, 2016. [ Journal Article ]
- Cell Cycle. 9(24): 4824-4835, 2010. [ Journal Article ]
Dr. Wang received his M.D. from the National Taiwan University and his Ph.D. in Cell Biology from the Weill Cornell Medicine of Cornell University. He completed his residency training in anatomic pathology and fellowship in hematopathology at the NCI, and joined the Laboratory of Pathology as a Staff Clinician in 2018.